ArticleBiotechnology letters2025
Expression of nisin in Scenedesmus acutus and evaluation of its antimicrobial activity.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microalgae, Cell Factories for Antimicrobial Peptides: A Promising Response to Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe study aimed to express a synthetic nisin gene in the nucleus of the green microalga Scenedesmus acutus UTEX 72 and evaluate its antimicrobial activity in vitro against Staphylococcus aureus (ATCC 29213), Enterococcus faecalis (ATCC 29212), and Listeria monocytogenes (ATCC 19118).
resultsNuclear transformation of S. acutus was achieved through co-culture with Agrobacterium tumefaciens. PCR analysis confirmed the presence of the Nis gene in the transformant lines, while ELISA quantified the total protein content. Results showed that nisin was predominantly expressed in the total soluble protein fraction, with the highest yield reaching 2.24 µg/µl. Antimicrobial assays demonstrated growth inhibition in all three tested Gram-positive bacteria. S. aureus and L. monocytogenes were inhibited after 60 min of exposure to 14.3 µg/ml of transgenic nisin, whereas E. faecalis needed 55 µg/ml and 180 min for inhibition. No antimicrobial activity was observed with wild-type S. acutus total soluble protein.
conclusionsNisin was successfully expressed in the nucleus of S. acutus, exhibiting antimicrobial activity against S. aureus, L. monocytogenes, and E. faecalis. These findings highlight S. acutus as a promising platform for the production of transgenic antimicrobial peptides, offering a potential alternative for combating pathogenic bacteria.
Indexed as
Identifiers
40504289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.